What question did this study set out to answer?

To assess the real-world prevalence of PD-L1 positivity in early-stage and metastatic triple-negative breast cancer (TNBC).

February 25, 2026Histopathology2 citationsOpen Access

View Full Paper

Real‐world prevalence of PD ‐ L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

CDCorrado D'Arrigo STSitki Tuzlali RBRomualdo Barroso‐Sousa

Key Points

To assess the real-world prevalence of PD-L1 positivity in early-stage and metastatic triple-negative breast cancer (TNBC).
Conducted a global retrospective observational study
Analyzed PD-L1 positivity rates based on local and central assessments
Compared prevalence between early-stage and metastatic TNBC
Evaluated the impact of sample size on PD-L1 results
Found lower prevalence of PD-L1 positivity in metastatic TNBC compared to early-stage TNBC
Noted that larger tissue samples showed higher PD-L1 positivity rates
Local assessments showed lower PD-L1 positivity rates than central assessments

Abstract

In this real-world study, PD-L1-positive prevalence was lower than in prospective trials assessing PD-L1 status centrally, lower in mTNBC than eTNBC, lower in smaller than larger tissue samples and lower by local than central assessment. These findings underline the importance of central PD-L1 testing on sufficiently large samples to ensure optimal selection for therapies targeting PD-(L)1 in mTNBC.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Real‐world prevalence of PD ‐ L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

Key Points

Abstract

Cite This Study